60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP – Get Free Report) saw a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 255,088 shares, an increase of 88.4% from the October 15th total of 135,408 shares. Approximately 7.4% of the shares of the company are sold short. Based on an average daily trading volume, of 1,664,816 shares, the days-to-cover ratio is presently 0.2 days.
60 Degrees Pharmaceuticals Stock Performance
Shares of NASDAQ SXTP traded down $0.00 during midday trading on Friday, reaching $0.52. The stock had a trading volume of 24,896 shares, compared to its average volume of 1,003,654. The stock has a 50-day moving average of $0.94 and a 200-day moving average of $1.65. The company has a market capitalization of $1.82 million, a price-to-earnings ratio of -0.11 and a beta of 2.47. 60 Degrees Pharmaceuticals has a 12-month low of $0.48 and a 12-month high of $8.62.
60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.16). The firm had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.20 million. As a group, analysts forecast that 60 Degrees Pharmaceuticals will post -3.31 EPS for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Research Report on SXTP
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for tropical and infectious diseases. The company’s work centers on treatments and preventive therapies for conditions that affect travelers, military personnel and populations in regions where infectious diseases are prevalent. Its lead product is Arakoda (tafenoquine), an oral prescription medicine approved by the U.S. Food and Drug Administration in 2018 for the prevention of malaria in adults.
Featured Stories
- Five stocks we like better than 60 Degrees Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
